Intra-Cellular Therapies, Inc. (ITCI)

Market Cap	5.88B
Revenue (ttm)	310.62M
Net Income (ttm)	-228.19M
Shares Out	95.93M
EPS (ttm)	-2.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	661,392
Open	60.09
Previous Close	59.53
Day's Range	59.03 - 61.66
52-Week Range	42.01 - 66.56
Beta	1.14
Analysts	n/a
Price Target	n/a
Earnings Date	May 4, 2023

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Dr. Sharon Mates Ph.D.
• Employees: 561
• Stock Exchange: NASDAQ
• Ticker Symbol: ITCI

Financial Performance

In 2022, ITCI's revenue was $250.31 million, an increase of 198.69% compared to the previous year's $83.80 million. Losses were -$256.26 million, -9.81% less than in 2021.